Arginine deprivation therapy for malignant melanoma
Author(s): Yoon JK | Frankel AE | Feun LG | Ekmekcioglu S | Kim KB
Volume: 2013
Issue: default
Year: 2012
Author(s): Yoon JK | Frankel AE | Feun LG | Ekmekcioglu S | Kim KB Volume: 2013 Issue: default Year: 2012
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
Author(s): Thomas RP | Recht L | Nagpal S
Volume: 2013
Issue: default
Year: 2012
Author(s): Thomas RP | Recht L | Nagpal S Volume: 2013 Issue: default Year: 2012
Immunocytokines: a review of molecules in clinical development for cancer therapy
Author(s): List T | Neri D
Volume: 2013
Issue: Supplement 1
Year: 2013
Author(s): List T | Neri D Volume: 2013 Issue: Supplement 1 Year: 2013
Use of ipilimumab in the treatment of melanoma
Author(s): Acharya UH | Jeter JM
Volume: 2013
Issue: Supplement 1
Year: 2013
Author(s): Acharya UH | Jeter JM Volume: 2013 Issue: Supplement 1 Year: 2013
Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma
Author(s): Brueseke TJ | Tewari KS
Volume: 2013
Issue: Supplement 1
Year: 2013
Author(s): Brueseke TJ | Tewari KS Volume: 2013 Issue: Supplement 1 Year: 2013
Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity
Author(s): Frankel AE
Volume: 2013
Issue: Supplement 1
Year: 2013
Author(s): Frankel AE Volume: 2013 Issue: Supplement 1 Year: 2013
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
Author(s): Portell CA | Wenzell CM | Advani AS
Volume: 2013
Issue: Supplement 1
Year: 2013
Author(s): Portell CA | Wenzell CM | Advani AS Volume: 2013 Issue: Supplement 1 Year: 2013
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
Author(s): Eskander RN | Tewari KS
Volume: 2013
Issue: Supplement 1
Year: 2013
Author(s): Eskander RN | Tewari KS Volume: 2013 Issue: Supplement 1 Year: 2013
A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
Author(s): van Rossem K | Lowe JA
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): van Rossem K | Lowe JA Volume: 2013 Issue: Issue 1 Year: 2013
Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes
Author(s): Di Pierro F | Putignano P | Villanova N | Montesi L | Moscatiello S | Marchesini G
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Di Pierro F | Putignano P | Villanova N | Montesi L | Moscatiello S | Marchesini G Volume: 2013 Issue: Issue 1 Year: 2013
Impact of denosumab on bone mass in cancer patients
Author(s): Brown-Glaberman U | Stopeck AT
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Brown-Glaberman U | Stopeck AT Volume: 2013 Issue: Issue 1 Year: 2013
Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
Author(s): Davis EM | Knezevich JT | Teply RM
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Davis EM | Knezevich JT | Teply RM Volume: 2013 Issue: Issue 1 Year: 2013
Effect of statin therapy on vaspin levels in type 2 diabetic patients
Author(s): Al-Azzam SI | Alzoubi KH | Abu Abeeleh J | Mhaidat NM | Abu-Abeeleh M
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Al-Azzam SI | Alzoubi KH | Abu Abeeleh J | Mhaidat NM | Abu-Abeeleh M Volume: 2013 Issue: Issue 1 Year: 2013
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)
Author(s): Bartosh NS | Tomlin T | Cable C | Halka K
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Bartosh NS | Tomlin T | Cable C | Halka K Volume: 2013 Issue: Issue 1 Year: 2013
High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
Author(s): Yabuno K | Seki M | Miyawaki K | Miwa Y | Tomono K
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Yabuno K | Seki M | Miyawaki K | Miwa Y | Tomono K Volume: 2013 Issue: Issue 1 Year: 2013
Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review
Author(s): Brennan JL | Leung JG | Gagliardi JP | Rivelli SK | Muzyk AJ
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Brennan JL | Leung JG | Gagliardi JP | Rivelli SK | Muzyk AJ Volume: 2013 Issue: Issue 1 Year: 2013
Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban
Author(s): Kwong LM
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Kwong LM Volume: 2013 Issue: Issue 1 Year: 2013
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
Author(s): Nanda K | Moss AC
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Nanda K | Moss AC Volume: 2013 Issue: Issue 1 Year: 2013
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
Author(s): Lozano R | Domeque N | Apesteguia AF
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Lozano R | Domeque N | Apesteguia AF Volume: 2013 Issue: Issue 1 Year: 2013
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Author(s): Upreti VV | Song Y | Wang J | Byon W | Boyd RA | Pursley JM | LaCreta F | Frost CE
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Upreti VV | Song Y | Wang J | Byon W | Boyd RA | Pursley JM | LaCreta F | Frost CE Volume: 2013 Issue: Issue 1 Year: 2013
Single-dose fentanyl sublingual spray for breakthrough cancer pain
Author(s): Taylor DR
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Taylor DR Volume: 2013 Issue: Issue 1 Year: 2013
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
Author(s): Wang X | Roy A | Hochhaus A | Kantarjian HM | Chen TT | Shah NP
Volume: 2013
Issue: Issue 1
Year: 2013
Author(s): Wang X | Roy A | Hochhaus A | Kantarjian HM | Chen TT | Shah NP Volume: 2013 Issue: Issue 1 Year: 2013
Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid
Author(s): Gandy JJ | Meeding JP | Snyman JR | Janse van Rensburg CE
Volume: 2012
Issue: default
Year: 2012
Author(s): Gandy JJ | Meeding JP | Snyman JR | Janse van Rensburg CE Volume: 2012 Issue: default Year: 2012
Erratum
Author(s): Samtani MN | Sheehan JJ | Fu D-J | Remmerie B | Sliwa JK | Alphs L
Volume: 2012
Issue: default
Year: 2012
Author(s): Samtani MN | Sheehan JJ | Fu D-J | Remmerie B | Sliwa JK | Alphs L Volume: 2012 Issue: default Year: 2012
Nortriptyline versus fluoxetine in the treatment of major depressive disorder: a six-month, double-blind clinical trial
Author(s): Hashemi SN | Ghafarian Shirazi HR | Mohammadi A | Zadeh-Bagheri GH | Noorian KH | Malekzadeh M
Volume: 2012
Issue: default
Year: 2012
Author(s): Hashemi SN | Ghafarian Shirazi HR | Mohammadi A | Zadeh-Bagheri GH | Noorian KH | Malekzadeh M Volume: 2012 Issue: default Year: 2012
Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features
Author(s): Seki M | Yabuno K | Miyawaki K | Miwa Y | Tomono K
Volume: 2012
Issue: default
Year: 2012
Author(s): Seki M | Yabuno K | Miyawaki K | Miwa Y | Tomono K Volume: 2012 Issue: default Year: 2012
Erratum
Author(s): Barrese V | Miceli F | Soldovieri MV | Ambrosino P | Iannotti FA | Cilio MR | Taglialatela M
Volume: 2012
Issue: default
Year: 2012
Author(s): Barrese V | Miceli F | Soldovieri MV | Ambrosino P | Iannotti FA | Cilio MR | Taglialatela M Volume: 2012 Issue: default Year: 2012
Sedation in the intensive care setting
Author(s): Hughes CG | McGrane S | Pandharipande PP
Volume: 2012
Issue: default
Year: 2012
Author(s): Hughes CG | McGrane S | Pandharipande PP Volume: 2012 Issue: default Year: 2012
Pazopanib for the treatment of soft-tissue sarcoma
Author(s): Heudel P | Cassier P | Derbel O | Dufresne A | Meeus P | Thiesse P | Ranchère-Vince D | Blay JY | Ray-Coquard I
Volume: 2012
Issue: default
Year: 2012
Author(s): Heudel P | Cassier P | Derbel O | Dufresne A | Meeus P | Thiesse P | Ranchère-Vince D | Blay JY | Ray-Coquard I Volume: 2012 Issue: default Year: 2012
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
Author(s): Kreutz RP | Nystrom P | Kreutz Y | Miao J | Desta Z | Breall JA | Li L | Chiang C | Kovacs R | Flockhart DA | Jin Y
Volume: 2012
Issue: default
Year: 2012
Author(s): Kreutz RP | Nystrom P | Kreutz Y | Miao J | Desta Z | Breall JA | Li L | Chiang C | Kovacs R | Flockhart DA | Jin Y Volume: 2012 Issue: default Year: 2012
Detemir as a once-daily basal insulin in type 2 diabetes
Author(s): Nelson SE
Volume: 2011
Issue: default
Year: 2011
Author(s): Nelson SE Volume: 2011 Issue: default Year: 2011
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
Author(s): Patel C | Li L | Girgis S | Kornhauser D | Frevert E | Boulton D
Volume: 2011
Issue: default
Year: 2011
Author(s): Patel C | Li L | Girgis S | Kornhauser D | Frevert E | Boulton D Volume: 2011 Issue: default Year: 2011
Drug-resistant tuberculosis: emerging treatment options
Author(s): Adhvaryu MR | Vakharia BC
Volume: 2011
Issue: default
Year: 2011
Author(s): Adhvaryu MR | Vakharia BC Volume: 2011 Issue: default Year: 2011
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
Author(s): Ohanian M | Cable CC | Halka KK
Volume: 2011
Issue: default
Year: 2011
Author(s): Ohanian M | Cable CC | Halka KK Volume: 2011 Issue: default Year: 2011
Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
Author(s): Ohanian M | Cable C | Halka K
Volume: 2011
Issue: default
Year: 2011
Author(s): Ohanian M | Cable C | Halka K Volume: 2011 Issue: default Year: 2011
Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
Author(s): Mahamid M | Mader R | Safadi R
Volume: 2011
Issue: default
Year: 2011
Author(s): Mahamid M | Mader R | Safadi R Volume: 2011 Issue: default Year: 2011
A case of cephalothin-associated urolithiasis
Author(s): Ivan WM Lim | Peter JO Stride | Robert L Horvath
Volume: 2011
Issue: default
Year: 2011
Author(s): Ivan WM Lim | Peter JO Stride | Robert L Horvath Volume: 2011 Issue: default Year: 2011
Lidocaine 5% patch for localized neuropathic pain: progress for the patient, a new approach for the physician
Author(s): Guy Hans | Dominique Robert | Johanna Verhulst | et al
Volume: 2010
Issue: default
Year: 2010
Author(s): Guy Hans | Dominique Robert | Johanna Verhulst | et al Volume: 2010 Issue: default Year: 2010
Nanoparticle-labeled stem cells: a novel therapeutic vehicle
Author(s): Abir O El-Sadik | Afaf El-Ansary | Sherif M Sabry
Volume: 2010
Issue: default
Year: 2010
Author(s): Abir O El-Sadik | Afaf El-Ansary | Sherif M Sabry Volume: 2010 Issue: default Year: 2010
The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease
Author(s): Heather E Vezina | Richard C Brundage | Thomas E Nevins | et al
Volume: 2010
Issue: default
Year: 2009
Author(s): Heather E Vezina | Richard C Brundage | Thomas E Nevins | et al Volume: 2010 Issue: default Year: 2009
Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent
Author(s): Gillian W Reierson | Claudio A Mastronardi | Julio Licinio | et al
Volume: 2009
Issue: Default
Year: 2009
Author(s): Gillian W Reierson | Claudio A Mastronardi | Julio Licinio | et al Volume: 2009 Issue: Default Year: 2009
